While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings.<h4>Objectives</h4>To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial.<h4>Methods</h4>We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. This evidence concerns the gene PPIG and atopic eczema.